Home > Insider Trading > Filing (0001209191-21-062981)

Filing Details

Accession Number:: 0001209191-21-062981
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-11-04 17:36:26
Reporting Period:: 2021-11-02

Accepted Time:: 2021-11-04 17:36:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689375	Entrada Therapeutics Inc.	TRDA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1473930	Todd Foley	C/O Mpm Capital 450 Kendall Street Cambridge MA 01242		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-11-02	3,816,760	$0.00	3,816,760	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-11-02	509,024	$0.00	4,325,784	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-11-02	100,000	$20.00	4,425,784	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2021-11-02	27,617,675	$0.00	3,816,760	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-11-02	3,683,241	$0.00	509,024	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The shares were converted as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
The shares are held as follows: 1,733,129 by BV 2014, 115,596 by BV 2014(B), 59,655 by AM BV2014, 1,778,737 by BV 2018, 94,538 by BV 2018(B) and 35,105 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein
The shares were converted as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares are held as follows: 1,964,268 by BV 2014, 131,013 by BV 2014(B), 67,611 by AM BV2014, 2,015,959 by BV 2018, 107,146 by BV 2018(B) and 39,787 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares were purchased as follows: 45,408 by BV 2014, 3,029 by BV 2014(B), 1,563 by AM BV2014, 46,603 by BV 2018, 2,477 by BV 2018(B) and 920 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares are held as follows: 2,009,676 by BV 2014, 134,042 by BV 2014(B), 69,174 by AM BV2014, 2,062,562 by BV 2018, 109,623 by BV 2018(B) and 40,707 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.